News

Neurology News Network for the week ending February 6, 2021.

The director of the Parkinson’s Disease and Movement Disorder Program at Emory University School of Medicine shared his perspective on the research and development of Parkinson therapies.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 5, 2021.

The RAISE trial will examine the proportion of patients with refractory status epilepticus who experience status cessation within 30 minutes of initiation of intravenous ganaxolone.

The annual meeting will now take place October 25–28, 2021 at the Rosen Shingle Creek in Orlando, Florida.

Researchers compared CMH rates in PSEN1, PSEN2, and APP mutation carriers and noncarriers of dominantly inherited Alzheimer disease.

The director of the Dartmouth Epilepsy Program provided an overview of some of the critical unmet needs within ongoing epilepsy research following the recent AES Annual Meeting.

Researchers also observed that PAP machines from ISPs were used for a longer median duration than those from DMEs.

Observation of pain freedom at 30 minutes was more accurate than the observation of relief at 30 minutes in predicting pain freedom at 2 hours.

The Evelyn F. McKnight Neurocognitive Scholar at the University of Miami Miller School of Medicine provided thoughts on why cognitive care and sleep disorder care should crossover more often.

Researchers found that time between assessments was the only predictor of PACC score differences.

Earlier AD diagnosis with the AlzoSure assay could potentially make it feasible to initiate disease-modifying therapies much earlier in the disease process.

The chief scientific officer of the Parkinson’s Foundation discussed strategies to close the gap between household income and telehealth use.

A score based on these variables was found to show good discrimination and calibration in predicting early neurological deterioration of ischemic origin, or ENDi.

The Cassava Sciences agent showed 6-month improvements in both ADAS-Cog and NPI scores, and a phase 3 trial is expected to begin in late 2021.

Episode 6 of the AUPN Leadership Minute features Mud M Alvi, MD, of West Virginia University and Robert C. Byrd Health; and David G Standaert, MD, PhD, of University of Alabama at Birmingham. [WATCH TIME: 4 minutes]

Gocovri is now the only therapy to be approved in the US to treat both off episodes and dyskinesia in patients with Parkinson disease.